Primary Idiopathic Myelofibrosis: Clinico-Epidemiological Profile and Risk Stratification in Pakistani Patients

  • Sultan, Sadia (Department of Hematology and Blood Bank, Liaquat National Hospital and Medical College) ;
  • Irfan, Syed Mohammed (Department of Hematology and Blood Bank, Liaquat National Hospital and Medical College)
  • Published : 2016.01.11


Background: Primary idiopathic myelofibrosis (PMF) is a clonal Philadelphia chromosome-negative myeloproliferative neoplasm characterized by extramedullary hematopoiesis and marrow fibrosis. It is an uncommon hematopoietic malignancy which primarily affects elderly individuals. The rational of this study was to determine its clinico-epidemiological profile along with risk stratification in Pakistani patients. Materials and Methods: In this retrospective cross sectional study, 20 patients with idiopathic myelofibrosis were enrolled from January 2011 to December 2014. Data were analyzed with SPSS version 22. Results: The mean age was $57.9{\pm}16.5years$ with 70% of patients aged above 50. The male to female ratio was 3:1. Overall only 10% of patients were asymptomatic and the remainder presented with constitutional symptoms. In symptomatic patients, major complaints were weakness (80%), weight loss (75%), abdominal discomfort (60%), night sweats (13%), pruritus (5%) and cardiovascular accidents (5%). Physical examination revealed splenomegaly as a predominant finding detected in 17 patients (85%) with the mean splenic span of $22.2{\pm}2.04cm$. The mean hemoglobin was $9.16{\pm}2.52g/dl$ with the mean MCV of $88.2{\pm}19.7fl$. The total leukocyte count of $17.6{\pm}19.2{\times}10^9/l$ and platelets count were $346.5{\pm}321.9{\times}10^9/l$. Serum lactate dehydrogenase, serum creatinine and uric acid were $731.0{\pm}154.1$, $0.82{\pm}0.22$ and $4.76{\pm}1.33$ respectively. According to risk stratification, 35% were in high risk, 40% in intermediate risk and 25% in low risk groups. Conclusions: The majority of PMF patients were male and presented with constitutional symptoms in our setting. Risk stratification revealed predominance of advanced disease in our series.


Clinico-epidemiological profile;primary idiopathic myelofibrosis;risk stratification


  1. Abelsson J, Merup M, Birgegard G, et al; Nordic MPD Study Group (2012). The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant, 47, 380-6.
  2. Abu-Hilal M, Tawaker J (2009). Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases.World J Gastroenterol, 15, 3128-33.
  3. Alchalby H, Yunus DR, Zabelina T, et al (2012). Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol, 157, 75-85.
  4. Benites BD, Lima CS, Lorand-Metze I, et al (2013). Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. Clinics Sao Paulo, 68, 339-43.
  5. Campbell PJ, Green AR (2011). Myeloproliferative neoplasms. In: Hoffbrand AV, Catovsky D, Tuddenham EG, Green AR. Post graduate hematology. Victor Hoffbrand, 6th edition, 701.
  6. Cervantes F, Passamonti F, Barosi G (2008). Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia, 22, 905-14.
  7. Cervantes F (2014). How I treat myelofibrosis. Blood, 124, 2635-42.
  8. Devos T, Zachee P, Bron D, et al (2015). Myelofibrosis patients in Belgium: disease characteristics. Acta Clin Belg, 70, 105-11.
  9. Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, et al (2015). Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Asian Pac J Cancer Prev, 16, 5013-8.
  10. Kiladjian JJ, Gisslinger H, Passamonti F, et al (2012). Healthrelated quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. J Clin Oncol, 30, 6626.
  11. Marchetti M, Barosi G, Balestri F, et al (2004). Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol, 22, 424-31.
  12. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A (1999). Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol, 61, 10-15.<10::AID-AJH3>3.0.CO;2-I
  13. Mitra D, Kaye JA, Piecoro LT, et al (2013). Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review. Cancer Med, 2, 889-98.
  14. Sag SO, Gorukmez O, Ture M, et al (2015). MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. Asian Pac J Cancer Prev, 16, 443-9.
  15. Sazawal S, Bajaj J, Chikkara S, et al (2010). Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Re, 132, 423-7.
  16. Tefferi A (2000). Myelofibrosis with myeloid metaplasia. N Engl J Med, 342, 1255-65.
  17. Thiele J, Kvasnicka HM, Orazi G, Tefferi A, Vardiman JM. Primary myelofibrosis. In: Swerdlow HS, Campo E, Haris LN, et al (2008). WHO classification of tumours of haemopoietic and lymphoid tissues. Lyon: International agency for research on cancer, 44.
  18. Vannucchi AM (2011). Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011, 222-30.
  19. Yang JJ, Chen H, Zheng XQ, et al (2015). Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm. Asian Pac J Cancer Prev, 16, 2219-25.